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Abstract: The goal of this study was to identify the optimal marker or marker combinations for detection of gastrointestinal malignancies
using reverse-transcriptase polymerase chain (RT-PCR) reaction. To detect the presence of tumors, we analyzed mucin 1 (MUC1),
cytokeratin 19 (CK19), cytokeratin 20 (CK20), and human telomerase reverse transcriptase (hTERT) mRNA in the peripheral blood
of 31 patients with gastrointestinal (esophagus, stomach, and colorectal) cancer and 30 healthy individuals. In RT-PCR analysis of the
peripheral blood, 77.4% (24/31), 61.29% (19/31), and 45.16% (14/31) of cancer patients were positive for MUC1, CK20, and hTERT
mRNA, respectively. According to our results, any one of these mRNA markers is a predictor of the presence of gastrointestinal tumors
(P < 0.001) and colorectal tumors (P < 0.05). However, they did not have predictive potential for presence of metastasis in gastrointestinal
tumors. As a result, combination of these 3 tumor-specific mRNA markers would increase the detection rate and may be clinically
helpful in predicting tumor presence.
Key words: Gastrointestinal cancer, reverse-transcriptase PCR

1. Introduction
The gastrointestinal tract is the most common site of
malignancies of any anatomic system in the body (Seregni
et al., 2001); every year an estimated 2.5 million people
are newly diagnosed (Boyle and Levin, 2008; Jemal et al.,
2011). Gastrointestinal tumors are often diagnosed at late
stages since patients with gastrointestinal tumors have a
very broad range of dyspeptic symptoms. Therefore, the
determining of sensitive and specific molecular markers
can be a useful clinical tool for the early detection and
management of diseases (Plaks et al., 2013). Because
of the heterogeneity of gastrointestinal tumors, a panel
of biomarkers for screening and diagnosis would be the
most appropriate (Lurje et al., 2010). Recently published
studies showed that detection of elevated circulating
tumor cells (CTCs) was a prognostic factor for metastatic
gastrointestinal cancers as well as an accurate indication
of rapid progression and mortality (Rahbari et al., 2010;
Rhim et al., 2012).
Detection of tumor cells in the blood could lead to a
search for epithelial-specific mRNAs, which might be
revealed in patients’ blood samples via amplification
by reverse transcription-polymerase chain reaction
(RT-PCR). The use of RT-PCR allows sensitive and
* Correspondence: sibelkucukyildirim@gmail.com
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reliable detection of a very small number of circulating
tumor cells in blood or bone marrow. RT-PCR assays
using epithelial markers are based on the principle that
carcinoma cells detach from the site of the primary tumor
and are distributed to hematopoietic or lymphatic tissue
(Alix-Panabières and Pantel, 2013). This can lead to the
appearance of gene transcripts that are not normally
expressed in these host tissues (Wang et al., 2006; Tsouma
et al., 2008).
Cytokeratins (CKs) such as CK19 and CK20 are
generally used for the detection of most epithelial tumors and
they belong to the epithelial subgroup of the intermediate
filament protein family that is involved in cell structure
and differentiation. Expression studies showed that CK19
expressed in all epithelial cells; however, CK20 is restricted
to gastrointestinal epithelium, urothelium, and Merkel cells
and this profile is maintained in malignant tumors of these
cells. The malignant nature of CK-positive cells in the bone
marrow has been confirmed through genomic analysis
using fluorescence in situ hybridization (Muller et al., 1996;
Stathopoulou et al., 2002). The relatively specific expression
of CKs by epithelial tissues and conservation of this cell
specificity following malignant transformation has led to their
widespread use as reliable markers for diagnostic pathology.
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Understandably, CKs have served as the most widely used
target for detection of metastasis from epithelial-derived
tumors in a variety of sites (Wlyd, 1998).
Tumor-associated protein mucin 1 (MUC1) is
also very often used to trace metastatic cancer cells in
gastrointestinal cancer (Uen et al., 2006; Lagoudianakis et
al., 2009). Mucins are involved in a variety of physiologic
functions including protection against mechanical and
infectious insults, lubrication, and acid resistance. An
increased expression of MUC1 in human and colorectal
cancer as a marker of progression and metastasis was
demonstrated previously (Nakamori et al., 1994; Baldus
et al., 2004). Telomerase, an enzyme responsible for
continuous cell growth, is repressed in most somatic cells
but activated in approximately 85% of human cancer
tissues (Hiyama and Hiyama, 2003). There were several
reports that human telomerase reverse transcriptase
(hTERT) mRNA is present in the peripheral blood of
patients with some cancer types (Chen et al., 2000; Shin et
al., 2002; Wang et al., 2006).
The current study aimed to evaluate the feasibility of
detection of MUC1, CK20, and hTERT mRNAs in the
peripheral blood of gastrointestinal cancer patients based
on RT-PCR amplification.
2. Materials and methods
2.1. Subjects
A total of 61 peripheral blood samples from 31
pathologically
confirmed
gastrointestinal
cancer
patients and 30 healthy subjects were collected from the
Department of Gastroenterology of the Gülhane Military
Medical Academy Hospital. The study was conducted
in compliance with the Helsinki Declaration and it was
approved by the institutional ethics committee; all patients
and healthy subjects involved gave their written informed
consent.
Clinicopathologic characteristics of the study
population are summarized in Table 1. All patients suffered
from adenocarcinomas. Clinical stages and pathologic
features of primary tumors were defined according to
the criteria of the American Joint Commission of Cancer
(Greene et al., 2001). All patients with gastrointestinal
cancer were found to have no evidence of other disease.
Ten milliliters of peripheral blood was drawn into an
EDTA tube and stored at 4 °C. As a positive control, RNA
samples were also prepared from the human colon cancer
cell line HT-29 (a gift from Dr G Selmanoğlu, Hacettepe
University, Ankara, Turkey).
2.2. Total RNA isolation and cDNA synthesis
Blood tubes were centrifuged at 1000 × g for 5 min; the buffy
coat was collected and transferred into 1.5-mL Eppendorf
tubes. Total RNA extraction was performed using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) according to the

Table 1. Patients’ characteristics.
Characteristic

n

Sex
Male

28

Female

3

Age
Median

63.3

Range
Tumor location

20–80
Stage I

Esophagus
Gastric
Colorectal

1

Stage II

Stage III

Stage IV

1

2

1

1

6

4

3

8

4

manufacturer’s instructions and the product was stored
at –80 °C until use. To avoid contamination of DNA
within RNA preparation, 1 µg of RNA was treated with
RNase-free DNase I, as recommended by the supplier
(New England BioLabs, Hitchin, UK). The first-strand
cDNA was synthesized from total RNA by using MuLV
reverse transcriptase (New England BioLabs). Total RNA
(1 µg) was reverse-transcribed in a final volume of 50 µL
containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM
MgCl2, 10 mM DTT, 0.2 mM oligo(dT)15, 0.2 mM dNTPs,
and 100 U of MuLV reverse transcriptase according to the
manufacturer’s guidelines.
The reaction mixtures with RNA were incubated at 42
°C for 1 h, heated to 95 °C for 5 min, and then stored at –20
°C until analysis.
2.3. PCR amplification
The quantity of isolated RNA was confirmed by
amplification of cDNA for house-keeping gene GAPDH.
Each PCR reaction mixture contained 1X PCR buffer
[67 mM Tris-HCl (pH 8.3), 16 mM (NH4)2SO4, 0.1%
Tween-20, 2.5 mM MgCl2], 0.1 mM dNTP, 0.1 µM sense
and antisense primers for target genes, and 1 U Taq DNA
polymerase (Bioron, Ludwigshafen am Rhein, Germany)
in a total volume of 25 µL. PCR products were analyzed
in 2.5% agarose gel. The signals on UV transilluminator
for each target gene and GAPDH expression levels were
analyzed with a computing densitometer (Syngene
GeneTools software) to calculate the relative mRNA
density ratio. The primer sequences, PCR conditions, and
predicted product size are given in Table 2.
2.4. Sequencing of PCR products
The amplified PCR products were sequenced using a Big
Dye sequencing system (Applied Biosystems, Carlsbad,
CA, USA) and determined to be identical to those
expected.
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Table 2. Primers and PCR conditions.
Primer

5’-3’ sequence

PCR conditions

Size of PCR
product (bp)

MUC1 (sense)

ACCTACCATCCTATGAGCGAG

(94 °C/30 s, 60 °C/30 s, 72 °C/30 s) × 35 cycles

228

MUC1 (antisense)

TGAAGAACCTGAGTGGAGTGGAAT

CK19 (sense)

TACCTGAAGAAGAACCATGAGGAG (94 °C/30 s, 60 °C/30 s, 72 °C/30 s) × 35 cycles

446

CK19 (antisense)

TGATTCTGCCGCTCACTATCAG

CK20 (sense)

CTGAATAAGGTCTTTGATGACC

CK20 (antisense)

CTGTGACCTGTTGCTGCAGAACT

hTERT (sense)

AAGTTCCTGCACTGGCTGAT

hTERT (antisense)

CACGACGTAGTCCATGTTCA

GAPDH (sense)

CCTCAAGATCATCAGCAATGC

GAPDH (antisense)

GGAAACTGTGGCGTGATGG

2.5. Statistical analysis
All analyses were conducted with SPSS 19. Potential
association between the expression of molecular markers
used in combination and the clinicopathologic features
of the study subjects were evaluated using 2 × 2 or 2
× k contingency tables and the significance of these
comparisons was assessed using 2-tailed Fisher’s exact
tests.
To evaluate the usefulness of gene expression levels
and presence/absence data of the 3 mRNA markers for
predicting overall tumor presence, metastasis status,
and colorectal tumor presence, we conducted separate
logistic regression analysis. Tumor presence, metastasis
status, and colorectal tumor presence were taken as binary
dependent variables and coded using 0 (absence of tumor
or metastasis) and 1 (presence of tumor or metastasis) as
dummy variables Significant fit of the regression equation
to the data was assessed using Wald statistics; however, the
cut-off for statistical significance was taken as P < 0.008
after Bonferroni correction for multiple comparisons. We
also calculated odds ratios (ORs) determining the strength
of association between predictive markers and tumor
presence.
Receiver operating characteristic (ROC) curve
analyses were done to analyze the RT-PCR data of MUC1,
CK20, and hTERT gene expression in the peripheral blood
of the subjects. The area under the ROC curve and the
corresponding 95% confidence intervals (95% CI) were
calculated for each marker. The cut-off value at the highest
accuracy level (minimal false-negative and false-positive
results) was determined.

850

(94 °C/30 s, 60 °C/30 s, 72 °C/30 s) × 35 cycles

295

(94 °C/30 s, 60 °C/30 s, 72 °C/30 s) × 35 cycles

265

(94 °C/30 s, 60 °C/30 s, 72 °C/30 s) × 35 cycles

165

3. Results
3.1. Expression of MUC1, CK20, and hTERT mRNAs in
peripheral blood samples from gastrointestinal cancer
patients
In analysis of the peripheral blood, 77.4% (24/31),
61.29% (19/31), and 45.16% (14/31) of cancer patients
were positive for MUC1, CK20, and hTERT mRNAs,
respectively. Seven (22.58%) of 31 patients were positive
for all 3 mRNAs. The sensitivity and specificity for any one
of the mRNAs detected in peripheral blood is 90.32% and
53.3%, respectively, with an accuracy of 68.85% (Table 3).
We used 2-tailed Fisher’s exact tests to analyze the
potential association between the expression of molecular
markers used in combination and the clinicopathologic
features of the study subjects. No association was
found between the presence of mRNA markers and
clinicopathologic characteristics of patients (Table 4).
For the 3 mRNA markers that we detected, there were
no differences between patients with different stages (P
> 0.05). Our results showed that combined analysis of
MUC1 and CK20 helps to decrease the false-positive rate
of detection (Table 3).
The predictive values of the 3 mRNA markers for tumor
presence were analyzed using univariate logistic regression
analysis (Tables 5 and 6). According to our results, any one
of these mRNA markers is a predictor of the presence of
gastrointestinal tumors (P < 0.001) and colorectal tumors
(P < 0.05). These markers do not have predictive value for
presence of metastasis in gastrointestinal tumors (Table 7).
ROC curve analyses of the RT-PCR data of the 61
subjects (31 cancer patients and 30 healthy individuals)
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Table 3. Sensitivity, specificity, and accuracy of MUC1, hTERT, and CK20 mRNA
markers and their combination.
Sensitivity

Specificity

Accuracy

MUC1

24/31 (77.4%)

8/30 (73.3%)

32/61 (52.4%)

CK20

19/31 (61.29%)

6/30 (80%)

25/61 (40.98%)

hTERT

14/31 (45.16%)

4/30 (86.6%)

18/61 (29.5%)

Any one mRNA

29/31 (93.54%)

14/30 (53.3%)

43/61(70.49%)

CK20+MUC1

17/31 (54.84%)

2/30 (93.3%)

19/61 (31.14%)

MUC1+hTERT

8/31 (25.80%)

2/30 (93.3%)

10/61 (16.39%)

CK20+hTERT

8/31 (25.80%)

1/30 (96.6%)

9/61 (14.75%)

MUC1+CK20+hTERT

7/31 (22.58%)

1/30 (96.6%)

8/61 (13.1%)

were done. The ROC curves for each mRNA marker are
shown in the Figure. Accordingly, the optimal cut-off value
and area under the ROC curve for each mRNA marker
was as follows: 2.00 and 0.795 (95% CI: 0.679–0.911) for
MUC1, 1.50 and 0.748 (95% CI: 0.625–0.871) for CK20,
and 3.00 and 0.673 (95% CI: 0.537–0.809) for hTERT.
3.2. Expression of MUC1, CK20, and hTERT mRNAs in
peripheral blood samples from healthy volunteers
MUC1, CK20, and hTERT markers were detected in
30 healthy volunteers. MUC1 expression was observed
in 8 (26.6%), CK20 expression in 6 (20%), and hTERT
expression in 4 (13.3%) samples.
The positive ratios of MUC1, CK20, and hTERT
mRNAs in gastrointestinal cancer patients are significantly
higher than in healthy subjects (Table 3).
4. Discussion
Developments in biotechnology have made it possible
to detect small numbers of tumor cells in peripheral
blood, and these cells would provide a useful monitoring,
diagnostic, and prognostic tool (Bednarz-Knoll et al.,
2011; Wicha and Hayes, 2011). In recent years, there have
been many reports on the RT-PCR detection of CTCs in
the peripheral blood, bone marrow, and/or peritoneal
lavage of patients with gastrointestinal cancer (Pantel et
al., 1999; Yamaguchi et al., 2000; Stathopoulou et al., 2002;
Gradilone et al., 2003; Dandachi et al., 2005; Uen et al.,
2006). Compared with bone marrow and lymph nodes,
blood collection is a minimally invasive procedure and
blood can be sampled throughout the course of the disease
(Böckmann et al., 2001; Huang et al., 2003; Pantel and
Alix-Panabières, 2010; Bednarz- Knoll et al., 2011).
Because of the heterogeneity of gastrointestinal tumors,
a panel of biomarkers could enhance the sensitivity of
CTC detection compared with the single markers in use
(Conzelmann et al., 2005; Lurje et al., 2010). The aim of
this work was to evaluate the feasibility of detection of
CTCs in the peripheral blood of gastrointestinal cancer

patients based on the RT-PCR amplification of MUC1,
CK20, and hTERT mRNAs, aiming to use a standardized
PCR method according to the World Health Organization
criteria for a screening test: acceptability, practicability,
high specificity, and high sensitivity (Kramer at al., 1999).
To evaluate the presence and predictive value of
MUC1, CK20, and hTERT in the peripheral blood of
gastrointestinal cancer patients, we analyzed 3 markers
in 31 cancer patients and 30 healthy individuals, and
we explored the correlation between expression of these
markers and tumor presence.
Because of its high sensitivity, RT-PCR based on the
amplification of the cell type-specific mRNA is increasingly
used to detect CTCs. In previous studies, many target
genes have been used to detect CTCs in gastrointestinal
carcinoma, such as CEA, MUC1, hTERT, cMet, CK18,
CK19, and CK20 (Soeth et al., 1997; Yamaguchi et al.,
2000; Katsumata et al., 2006; Uen et al., 2006; Wu et al.,
2006; Xi et al., 2007; Tsouma et al., 2008; Lagoudianakis
et al., 2009). Cytokeratins are frequently used to detect the
CTCs in peripheral blood (Weitz et al., 1999; Gradilone
et al., 2003; Wang et al., 2006; Wang et al., 2007). The
mRNAs of CK19 and CK20 have been successfully used to
detect CTCs in the peripheral blood of patients with breast
cancer, lung cancer, and gastrointestinal carcinoma (Mori
et al., 1996; Denis et al., 1997; Peck et al., 1998). Wlyd
et al. (1998) suggested that CK20 may be a useful target
for RT-PCR detection of epithelial-derived cancers than
previously described in cytokeratins.
In our study, in RT-PCR analysis of the peripheral
blood, 77.4% (24/31), 61.29% (19/31), and 45.16% (14/31)
of cancer patients were positive for MUC1, CK20, and
hTERT mRNAs, respectively. When combining MUC1,
CK20, and hTERT mRNA markers for the detection of
CTCs in gastrointestinal cancer patients, the sensitivity of
the detection rate increased up to 90.32% (28/31) and the
rate of false positives was 3.33% (1/30). No correlation was
found between the presence of MUC1, CK20, and hTERT

851

852

8

Healthy individuals (n = 30)

7

<60

9

12

Gastric

Colorectal

5

12

6

2

3

4

18

6

M0

M1

Metastasis

1

1

Stage

3

Esophagus

Tumor location

17

≥60

Age

24

Patients (n = 31)

3

4

4

3

0

0

4

2

1

4

3

7

22

0.384

0.350

1.000

0.210

5

14

5

10

3

1

12

6

1

8

11

<0.001 6

19

+

P

+

-

CK20

MUC1

4

8

5

5

2

0

4

5

3

3

9

24

12

-

0.704

0.871

0.154

0.452

0.002

P

3

11

3

9

1

1

7

6

1

5

9

4

14

+

hTERT

Table 4. Clinicopathological features of patients with or without mRNA expression.

6

11

7

6

4

0

9

5

3

6

11

26

17

29

+

0.456

0.200

0.611

1.000

8

21

8

15

5

1

14

11

4

11

18

<0.001 14

P

1

1

2

0

0

0

2

0

0

0

2

16

2

-

Any 1 mRNA

0.503

0.183

0.622

0.527

0.000

P

5

16

5

12

3

1

12

8

1

7

14

3

21

+

4

6

5

3

2

0

4

3

3

4

6

27

10

-

Any 2 mRNAs

7

+

0.417

0.385

0.197

1.000

1

6

1

4

1

1

5

2

0

2

5

<0.001 1

P

8

16

9

11

4

0

11

9

4

9

15

29

24

-

All 3 mRNAs

0.640

0.314

0.593

0.664

0.053

P
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Table 5. Results of logistic regression analysis for predicting tumor presence based on gene expression and presence/
absence data of mRNA markers.

Markers

B

SE

Wald

df

Sig.

Odds ratio
exp(B)

Odds ratio (95% CI)
Lower

Upper

MUC1/GAPDH

2.454

0.827

8.809

1

0.003

11.631

2.301

58.792

CK20/GAPDH

3.004

1.002

8.987

1

0.003

20.165

2.829

143.721

hTERT/GAPDH

0.002

0.003

0.381

1

0.537

1.002

0.996

1.008

Any 1

–2.808

0.818

11.794

1

0.001

0.060

0.012

0.300

Any 2

–2.939

0.720

16.677

1

0.000

0.053

0.013

0.217

All 3

–2.135

1.104

3.740

1

0.053

0.118

0.014

1.029

Table 6. Results of logistic regression analysis for predicting colorectal tumor presence based on gene expression and
presence/absence data of mRNA markers.

Markers

B

SE

Wald

df

Sig.

Odds ratio
exp(B)

Odds ratio (95% CI)
Lower

Upper

MUC1/GAPDH

0.552

0.563

0.961

1

0.327

1.737

0.576

5.243

CK20/GAPDH

1.930

0.933

4.283

1

0.038

6.892

1.108

42.878

hTERT/GAPDH

–0.002

0.003

0.387

1

0.534

0.998

0.992

1.004

Any 1

21.411

2.85E+04

0.000

1

0.999

1.9E+09

0.000

Inf.

Any 2

–0.875

0.827

1.122

1

0.290

0.417

0.082

2.106

All 3

–1.253

0.934

1.801

1

0.180

0.286

0.046

1.780

Table 7. Results of logistic regression analysis for predicting the presence of metastasis based on gene expression and
presence/absence data of mRNA markers.

Markers

B

SE

Wald

df

Sig.

Odds ratio
exp(B)

Odds ratio (95% CI)
Lower

Upper

MUC1/GAPDH

–1.102

0.779

2.002

1

0.157

0.332

0.072

1.529

CK20/GAPDH

–0.485

0.867

0.313

1

0.576

0.616

0.112

3.370

hTERT/GAPDH

–0.002

0.005

0.173

1

0.677

0.998

0.989

1.007

Any 1

0.965

1.474

0.429

1

0.513

2.625

0.146

47.183

Any 2

1.001

0.842

1.413

1

0.235

2.720

0.522

14.165

All 3

1.099

1.164

0.891

1

0.345

3.000

0.307

29.353

markers and clinicopathologic characteristics of patients
(Table 4).
In this study, in RT-PCR analysis of the peripheral blood
of cancer patients and healthy individuals, 100% (61/61)
were positive for CK19. Due to the high false-positive rate,
CK19 is not useful for CTC detection. Similarly to our results,
other investigators have also detected CK19 transcripts in
the peripheral blood of healthy individuals (Krismann et al.,

1995; Stathopoulou et al., 2002; Wu et al., 2006). The false
positive in healthy individuals might be attributed to the
design of primers, pseudogenes, contamination of epithelial
cells, or the handling of samples (Ruud et al., 1999; Wang
et al., 2006; Tsouma et al., 2008). These may involve the
ectopic expression of the CK19 gene in hematopoietic cells
or the expression of any gene in any cell type (Chelly et al.,
1989; Novaes et al., 1997; Stathopoulou et al., 2002).
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Figure. ROC curves for MUC1, CK20, and hTERT mRNAs from analysis of RTPCR data of 61 subjects. Sensitivity (Y axis) was plotted against the false-positive
fraction (1-specificity; X axis) for various cut-off values.

In the literature, different frequencies for MUC1, CK20,
and hTERT in patients have been described (Noguchi et
al., 1996; de Cremoux et al., 2000; Katsumata et al., 2006;
Uen et al., 2006). The differences could be explained by
the heterogeneous designs of these studies (number of
samples, sampling methods, tumor sites, tumor stages,
RNA extraction, and PCR protocols). Improved sensitivity
in patients may be achieved by analysis of larger blood
volumes and analysis of multiple samples from one
individual. This method may reduce false-negative
results (Wlyd et al., 1998). Jonas et al. (1997) reported an
increased rate of CEA detection by RT-PCR in peripheral
blood samples from patients with colorectal cancer
when 3 separate samples were analyzed. CTC detection
methods also need to be taken into account, as sensitivity
and specificity are of major importance and may differ
significantly. Thus, it will be important to define the
critical variables in the methods and to introduce at least
some level of standardization to allow for more reliable
and reproducible results (Pantel et al., 1999; Vlems et al.,
2002; Uen et al., 2006; Khair et al., 2007).
In our study, we found that MUC1, CK20, and hTERT
mRNAs are significantly more frequently detected in
gastrointestinal cancer patients than in healthy controls
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and could serve as markers. Funaki et al. (1998) detected
CK20 mRNA in the peripheral blood of advanced colorectal
carcinoma patients, which seems to present an indicator
of possible recurrence in individual patients. It has been
suggested that CK20 mRNA detection by RT-PCR in the
peripheral blood and bone marrow is a promising marker
for circulating tumor cells of epithelial origin (Burchill et
al., 1995; Johnson et al., 1995; Soeth et al., 1997; Katsumata
et al., 2006).
In the univariate analysis, there was statistically
significant association between the detection of any one
mRNA and tumor presence (P < 0.001). These results
clearly demonstrate the significant and prognostic/
predictive value of MUC1, CK20, and hTERT mRNA
detection by RT-PCR in the peripheral blood of patients
with gastrointestinal cancers. Similar to our results,
Msaouel and Koutsilieris (2011) reported that CTC
evaluation can confirm tumor diagnosis.
Other studies showed MUC1, CK20, and hTERT
expressions in peripheral blood of healthy individuals
(de Cremoux et al., 2000; Gradilone et al., 2003; Uen et
al., 2006; Wu et al., 2006; Wang et al., 2007). Illegitimate
transcription of tissue-specific genes in blood from
healthy individuals has been previously described by the
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mononuclear fraction. Sources of illegitimate expression
of MUC1, CK20, and hTERT mRNAs are macrophages,
lymphocytes, and hematopoietic cells. Illegitimate
transcription in blood cells is a well-known limitation and
lowers the specificity of the RT-PCR analysis. While using
RT-PCR in CTC detection could overcome the problems
of lack of sensitivity associated with other methods, the
selection of epithelial-specific mRNA is difficult (Solmi et
al., 2006).
Our study demonstrated that MUC1, CK20, and
hTERT gene expressions differ between individuals even
if they have the same tumor type. Therefore, marker
combinations maximize differences in expression in
tumors compared with cells isolated from normal blood.
Due to the heterogeneity of the expression of tumor-related
genes, a multimarker assay is regarded as more reliable and
sensitive than a single marker assay (Conzelmann et al.,
2005; Lurje et al., 2010).

In this study, we found that the detection of MUC1,
CK20, and hTERT mRNAs in the peripheral blood of
patients with gastrointestinal cancers is a significant
predictive/prognostic factor for determining tumor
presence. This method could offer a simple, noninvasive,
and promising tool for the detection of CTCs. However,
a further study in larger patient and healthy populations
is required to confirm the clinical usefulness of these
molecular markers. Moreover, in order to arrive at a highly
significant conclusion, a further study is to be performed
with a particular tumor type, such as focusing on the
stomach.
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